A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS). - Trial NCT05975905
Access comprehensive clinical trial information for NCT05975905 through Pure Global AI's free database. This Phase 2 trial is sponsored by Keros Therapeutics, Inc. and is currently Recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Keros Therapeutics, Inc.
Timeline & Enrollment
Phase 2
Jun 27, 2023
Jan 31, 2027
Primary Outcome
Change from Baseline in PVR (Pulmonary Vascular Resistance)
Summary
Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to
 determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO
 Group 1 PH) on stable background PAH therapy. The study is divided into the Screening Period,
 Treatment Period, Extension Period, and Follow-Up Period.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05975905
Non-Device Trial